PHIO
Phio Pharmaceuticals Corp.
Biotechnology
Market Cap$7M
5Y Perf.-99.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PHIO vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
PHIO vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PHIO | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $7M | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-8M | $-168M |
| Total Debt | $0.00 | $22M |
| Cash & Equiv. | $21M | $194M |
PHIO vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PHIO
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Phio Pharmaceutical… (PHIO) | 100 | 0.3 | -99.7% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PHIO vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DBVT leads in 2 of 4 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Phio Pharmaceuticals Corp. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
PHIO
Phio Pharmaceuticals Corp.
The Income Pick
PHIO is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.59
- EPS growth -59.3%
- -75.8% ROA vs DBVT's -89.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Long-Run Compounder
DBVT carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -87.0% 10Y total return vs PHIO's -100.0%
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | DBVT | Beta 1.26 vs PHIO's 1.59 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.4% vs PHIO's -44.1% |
| Efficiency (ROA) | PHIO | -75.8% ROA vs DBVT's -89.0% |
PHIO vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDBVTLAGGINGPHIO
PHIOPhio Pharmaceuticals …
2leads
DBVTDBV Technologies S.A.
3leads
6 Total Categories
CATEGORYLEADERvs PHIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
PHIO2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PHIO3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT6/6
Risk & VolatilityBeta, volatility, and downside exposure
DBVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PHIO and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | PHIOPhio Pharmaceutic… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$8M | -$112M |
| Net IncomeAfter-tax profit | -$8M | -$168M |
| Free Cash FlowCash after capex | -$7M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +71.4% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
PHIO leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | PHIOPhio Pharmaceutic… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $7M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | -$14M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -0.79x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.34x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
PHIO leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
PHIO leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
PHIO delivers a -86.4% return on equity — every $100 of shareholder capital generates $-86 in annual profit, vs $-130 for DBVT. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs PHIO's 2/9, reflecting mixed financial health.
| Metric | PHIOPhio Pharmaceutic… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -86.4% | -130.2% |
| ROA (TTM)Return on assets | -75.8% | -89.0% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | — | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | -$21M | -$172M |
| Cash & Equiv.Liquid assets | $21M | $194M |
| Total DebtShort + long-term debt | $0 | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
PHIO leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $40 for PHIO. Over the past 12 months, DBVT leads with a +110.4% total return vs PHIO's -44.1%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs PHIO's -68.3% — a key indicator of consistent wealth creation.
| Metric | PHIOPhio Pharmaceutic… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +4.6% | +4.9% |
| 1-Year ReturnPast 12 months | -44.1% | +110.4% |
| 3-Year ReturnCumulative with dividends | -96.8% | +19.7% |
| 5-Year ReturnCumulative with dividends | -99.6% | -69.1% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -68.3% | +6.2% |
DBVT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than PHIO's 1.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs PHIO's 27.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PHIOPhio Pharmaceutic… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.59x | 1.26x |
| 52-Week HighHighest price in past year | $4.19 | $26.18 |
| 52-Week LowLowest price in past year | $0.81 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +27.2% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 43.1 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 264K | 252K |
DBVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PHIOPhio Pharmaceutic… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $46.33 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 3 of 6 categories (Income & Cash Flow, Total Returns). PHIO leads in 2 (Valuation Metrics, Profitability & Efficiency).
Best OverallDBV Technologies S.A. (DBVT)Leads 3 of 6 categories
Loading custom metrics...
PHIO vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PHIO or DBVT a better buy right now?
Analysts rate DBV Technologies S.
A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PHIO or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -99. 6% for Phio Pharmaceuticals Corp. (PHIO). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus PHIO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PHIO or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Phio Pharmaceuticals Corp. 's 1. 59β — meaning PHIO is approximately 27% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — PHIO or DBVT?
On earnings-per-share growth, the picture is similar: Phio Pharmaceuticals Corp.
grew EPS -59. 3% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PHIO or DBVT?
Phio Pharmaceuticals Corp.
(PHIO) is the more profitable company, earning 0. 0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHIO leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — PHIO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PHIO or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PHIO or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Phio Pharmaceuticals Corp. (PHIO) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, PHIO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PHIO and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.